•  
  •  
  •  
  •  

2026-02-10 00:52:42

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • UVS Hospitality and Services Ltd announces strategic fundraise and acquisition of Calcio Restaurants in major Expansion Move
  • Cholamandalam Financial Holdings Ltd 9M FY26 consolidated PAT at Rs. 3860 crores
  • Strategic Boost to Atmanirbharta in Shipbuilding as GRSE and HSL Sign MoU
  • India needs nearly 2,000 Exploration Licenses in oil and gas to become energy secured says, Vedanta Group Chairman
  • Nifty steadies after gap-up, recovery attempts gain traction

Keywords Selected:  Tablets

Stock Report

  • NATCO receives Tentative Approval for Erdafitinib Tablets from USFDA
  • Senores Pharmaceuticals, Inc. announces the approval and launch of Deferiprone Tablets USP, 500 mg & 1000 mg
  • NATCO announces launch of its Everolimus tablets, 1 mg, (generic of Zortress®)
  • Relonchem Limited receives Marketing Authorization for its products
  • NATCO launches Bosentan Tablets for Oral Suspension in the United States with 180-day exclusivity
  • Lupin launches Bosentan Tablets for Oral Suspension in the United States with 180-Day Exclusivity
  • Shilpa Medicare announces the approval of Nor Ursodeoxycholic Acid Tablets 500 mg for the treatment of Non‐Alcoholic Fatty Liver Disease in India
  • Zydus receives tentative approval from USFDA for Rifaximin Tablets, 550 mg
  • Lupin launches Eslicarbazepine Acetate Tablets in the United States
  • Wanbury Limited launching two new products, Formulation - Branded Hematinic Iron tablets, WANBURY C-RED and API- KETAMINE HYDROCHLORIDE
  • Zydus receives final approval from USFDA for Eluxadoline Tablets, 75 mg and 100 mg
  • Lupin Launches Rivaroxaban Tablets USP, 2.5mg in the United States
  • Eugia Pharma receives USFDA Approval for Pazopanib Tablets, 200 mg
  • Aurobindo Pharma receives USFDA Approval for Cephalexin Tablets USP, 250 mg and 500 mg
  • Alembic Pharmaceuticals announces USFDA Final Approval for Paliperidone Extended Release Tablets, 1.5 mg, 3 mg, 6 mg, and 9 mg
  • Lupin Enters into a Non-Exclusive Patent Licensing Agreement with Takeda to Commercialize Vonoprazan, a Novel Gastrointestinal Drug in India
  • Alembic Pharmaceuticals announces USFDA Final Approval for Albendazole Tablets USP, 200 mg
  • Lupin Launches Mirabegron Extended-Release Tablets in the United States
  • Sun Pharma introduces a novel treatment, STARIZO in India for acute bacterial skin and skin structure infections
  • Indoco Remedies receives USFDA final ANDA approval for Lofexidine Tablets 0.18 mg with Competitive Generic Therapy designation
  • Alembic Pharmaceuticals announces USFDA Final Approval for Fluphenazine Hydrochloride Tablets USP, 1 mg, 2.5 mg, 5 mg, and 10 mg
  • Zydus receives final approval from USFDA for Valsartan Tablets
  • Dr. Reddy's signs non-exclusive patent licensing agreement with Takeda to commercialise Vonoprazan
  • Zydus receives final approval from USFDA for Sacubitril and Valsartan Tablets

Latest Post

  • UVS Hospitality and Services Ltd announces strategic fundraise and acquisition of Calcio Restaurants in major Expansion Move
  • Cholamandalam Financial Holdings Ltd 9M FY26 consolidated PAT at Rs. 3860 crores
  • Strategic Boost to Atmanirbharta in Shipbuilding as GRSE and HSL Sign MoU
  • India needs nearly 2,000 Exploration Licenses in oil and gas to become energy secured says, Vedanta Group Chairman
  • Nifty steadies after gap-up, recovery attempts gain traction


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025